Sengstake S, Rigouts L. A multicenter evaluation of the Genoscholar PZA-TB II line probe assay to detect pyrazinamide resistance in Mycobacterium tuberculosis isolates: study report. Institute of Tropical Medicine, Antwerp. 2020.
Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis. Geneva: World Health Organization; 2020 (https://www.who.int/publications/i/item/meeting-report-of-the-who-expert-consultation-on-the-definition-of-extensively-drug-resistant-tuberculosis).
Technical report on critical concentrations for TB drug susceptibility testing of medicines used in the treatment of drug-resistant TB. Geneva: World Health Organization; 2018 (https://www.who.int/publications/i/item/WHO_CDS_TB_2018.5).
Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis (WHO/CDS/TB/2018.24). Geneva: World Health Organization; 2018 (https://www.who.int/publications/i/item/9789241514842).
World Health Organization, Foundation for Innovative New Diagnostics. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide (WHO/CDS/TB/2018.19). Geneva: World Health Organization; 2018 (https://apps.who.int/iris/bitstream/handle/10665/274443/WHO-CDS-TB-2018.19-eng.pdf).
Technical guide on next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex. Geneva: World Health Organization; 2018 (https://www.who.int/publications/i/item/WHO-CDS-TB-2018.19).
Chest radiography in tuberculosis detection: summary of current WHO recommendations and guidance on programmatic approaches. Geneva: World Health Organization; 2016 (https://www.who.int/publications/i/item/9789241511506).
GLI practical guide to TB laboratory strengthening. Geneva: Global Laboratory Initiative; 2017 (http://stoptb.org/wg/gli/gat.asp).
ISO 15189: 2012 Medical laboratories - requirements for quality and competence. Geneva: International Organization for Standardization; 2017 (https://www.iso.org/standard/56115.html).
Van Deun A, Aung KJM, Bola V, Lebeke R, Hossain MA, de Rijk WB et al. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol. 2013;51(8):2633-40 (https://pubmed.ncbi.nlm.nih.gov/23761144).
Berhanu RH, Schnippel K, Kularatne R, Firnhaber C, Jacobson KR, Horsburgh CR et al. Discordant rifampicin susceptibility results are associated with Xpert MTB/RIF probe B and probe binding delay. Int J Tuberc Lung Dis. 2019;23(3):358-62.
Ngabonziza JCS, Decroo T, Migambi P, Habimana YM, Van Deun A, Meehan CJ et al. Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in Rwanda. Lancet Microbe. 2020;1(2):e74-e83 (https://doi.org/10.1016/S2666-247(20)30007-0).
Beylis N, Ghebrekristos Y, Nicol M. Management of false-positive rifampicin resistant Xpert MTB/ RIF. Lancet Microbe. 2020;1(6):e238 (https://doi.org/10.1016/S2666-5247(20)30123-3).
Chakravorty S, Simmons AM, Rowneki M, Parmar H, Cao Y, Ryan J et al. The new Xpert MTB/RIF Ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing. mBio. 2017;8(4):e00812-17 (https://pubmed.ncbi.nlm.nih.gov/28851844).
Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2018;18(1):76-84 (https://doi.org/10.1016/S1473-3099(17)30691-6).
Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014;2014(1):CD009593 (https://pubmed.ncbi.nlm.nih.gov/24448973).
Cao Y, Parmar H, Gaur RL, Lieu D, Raghunath S, Via N et al. Xpert MTB/XDR: a 10-color reflex assay suitable for point-of-care settings to detect isoniazid, fluoroquinolone, and second-line-injectable-drug resistance directly from Mycobacterium tuberculosis-positive sputum. Journal of clinical microbiology. 2021;59(3):e02314-20.
Sanchez-Padilla E, Merker M, Beckert P, Jochims F, Dlamini T, Kahn P et al. Detection of drug-resistant tuberculosis by Xpert MTB/RIF in Swaziland. N Engl J Med. 2015;372(12):1181-2.
Ismail NA, McCarthy K, Conradie F, Stevens W, Ndjeka N. Multidrug-resistant tuberculosis outbreak in South Africa. Lancet Infect Dis. 2019;19(2):134-5 (https://doi.org/10.1016/S1473-3099(18)30715-1).
Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV. Policy update. Geneva: World Health Organization; 2019 (https://www.who.int/publications/i/item/9789241550604).
Ismail NA, Aono A, Borroni E, Cirillo DM, Desmaretz C, Hasan R et al. A multimethod, multicountry evaluation of breakpoints for bedaquiline resistance determination. Antimicrob Agents Chemother. 2020;64(9):e00479-20 (http://aac.asm.org/content/64/9/e00479-20.abstract).
Dean AS, Zignol M, Cabibbe AM, Falzon D, Glaziou P, Cirillo DM et al. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data. PLoS Med. 2020;17(1):e1003008 (https://doi.org/10.1371/journal.pmed.1003008).
Cao Y, Parmar H, Gaur RL, Lieu D, Raghunath S, Via N et al. Xpert MTB/XDR: A 10-color reflex assay suitable for point of care settings to detect isoniazid-, fluoroquinolone-, and second-line-injectable-drug resistance directly from Mycobacterium tuberculosis-positive sputum. bioRxiv.2020:2020.09.08.288787 (http://biorxiv.org/content/early/2020/09/09/2020.09.08.288787.abstract).